All Individual Drugs Already Approved

Approved for 30 Other Conditions

No Placebo-Only Group

Pivotal Trial

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Chemotherapy + Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

This study is evaluating whether a combination of 2 monoclonal antibodies plus chemotherapy is more effective than a combination of 2 monoclonal antibodies plus chemotherapy in treating patients with newly diagnosed non-Hodgkin's lymphoma.

I have never received monoclonal antibody treatment for cancer.

My lymphoma has not spread to my brain or spinal cord.

I have been diagnosed with congestive heart failure.

I have been diagnosed with cardiomyopathy.

I haven't had any cancer in the last 5 years, except for certain skin cancers or cervical pre-cancer.

I have not had radiation therapy for lymphoma.

I have not had chemotherapy for lymphoma before.

My condition is graded between I and III.

I can take care of myself and am up and about more than half of my waking hours.

I have a type of lymphoma that has not been treated and is in an advanced stage.

Cyclophosphamide

Doxorubicin

Rituximab

Tositumomab

Vincristine

Approved for 10 Other Conditions

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or without radiation therapy and/or surgery in treating Ewing's sarcoma.

PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Combination Chemotherapy for Ewing's Sarcoma

This study is evaluating whether a combination of chemotherapy and radiation therapy is more effective than chemotherapy alone in treating Ewing's sarcoma.

My cancer is a type of Ewing's sarcoma or related.

My disease is either operable, was operated on, needs or doesn’t need immediate radiotherapy, has spread to lungs/pleura or beyond, and it’s been less than 45 days since my definitive biopsy.

My kidney function is normal, with a filtration rate of 60 mL/min or more.

My heart functions normally, with good pumping ability.

I don't have any health or social issues that would stop me from joining the study.

Autologous Hematopoietic Stem Cell Transplantation

Busulfan

Conventional Surgery

Dactinomycin

Doxorubicin Hydrochloride

Etoposide

Ifosfamide

Melphalan

Radiation Therapy

Vincristine Sulfate

This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Isotretinoin +/- Immunotherapy for Neuroblastoma

This study is evaluating whether a combination of chemotherapy, isotretinoin, dinutuximab, aldesleukin, and sargramostim is more effective than chemotherapy alone in treating patients with neuroblastoma.

My heart's pumping ability is confirmed to be normal by recent tests.

I have high-risk neuroblastoma, or it became high-risk after initial diagnosis.

I completed therapy for my cancer, including intensive treatment and a stem cell transplant.

My seizures are under control with medication and I have no severe brain-related side effects.

My parent or guardian has given written consent for me to participate.

I am eligible for a second stem cell transplant.

My latest bone marrow tests show less than 10% tumor cells before my stem cell transplant or joining this study.

I started my first chemotherapy for high-risk neuroblastoma less than 12 months ago.

I've had recent scans and tests to check my cancer's stage before joining the trial.

I've completed therapy for neuroblastoma, including intensive treatments and possibly surgery.

I am eligible for a tandem transplant and have followed specific treatment protocols within the last 12 months.

My veno-occlusive disease is stable or getting better.

My lung function tests are above 60% of what's expected, or I'm a child without breathing issues.

My neuroblastoma shows a positive response according to specific criteria before stem cell transplant.

My kidney function is within the required range for my age and gender.

I have never received GD2 antibody therapy.

I can do most activities and my doctor thinks I have at least 2 months to live.

I still have cancer after radiotherapy but haven't had a biopsy.

My neuroblastoma shows a positive response to treatment before stem cell transplant.

My kidney function is normal or near normal.

Aldesleukin

Dinutuximab

Isotretinoin

Sargramostim

The goal of the Early Treatment for Retinopathy of Prematurity Study (ETROP) is to test the hypothesis that earlier treatment in carefully selected cases will result in an overall better visual outcome than treatment at the conventional CRYO-ROP threshold point in the disease.

The Early Treatment for Retinopathy of Prematurity Study (ETROP)

Early Treatment for Retinopathy of Prematurity

This study is evaluating whether early treatment of retinopathy of prematurity (ROP) can improve vision.

My baby was born weighing less than 1251 grams and was either born at or examined by a participating center within 42 days of life.

My infant has a severe eye condition due to premature birth.

Early Treatment

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

T900607-Sodium for Liver Cancer

This study is evaluating whether a drug called T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

I have severe heart issues, including weak heart pumping or chest pain.

I have not had any cancer other than skin cancer or cervical carcinoma in situ in the past 5 years.

I have had cancer spread to my brain or its coverings.

I've had treatments for liver cancer but it's been over 6 weeks since, and I have a new or growing tumor.

My liver cancer diagnosis was confirmed through tissue examination.

I have not had chemotherapy or radiotherapy for my liver cancer.

I am able to care for myself but cannot do normal activities or work.

I have a tumor that can be seen and measured on a CT scan.

I have not had major surgery in the last 4 weeks.

My liver function is classified as either good or moderately good.

T900607-Sodium

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Immunotherapy with DCVax-L for Brain Cancer

This study is evaluating whether a vaccine can improve survival for people with brain cancer.

I stopped taking steroids at least 10 days before my leukapheresis.

My initial treatment was surgery to remove as much of the tumor as possible, followed by radiation and Temodar chemotherapy.

I agree not to receive certain cancer treatments except for temozolomide as per the Stupp Protocol while on DCVax-L.

My tumor sample from surgery is enough for the protein test.

I have enough DCVax-L available for treatment after it was made.

I have been diagnosed with Grade IV brain cancer in one side of my brain.

My bone marrow, liver, and kidneys are working well.

I am between 18 and 70 years old and can legally consent.

My cancer did not worsen after finishing radiation therapy.

DCVax®-L

This randomized phase IIB trial studies imatinib mesylate at two different doses and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia. Imatinib mesylate or dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Imatinib or Dasatinib for Chronic Myeloid Leukemia

This study is evaluating whether a drug called imatinib mesylate or dasatinib can stop the growth of cancer cells in patients with chronic myelogenous leukemia.

I haven't had major surgery in the last 28 days and have recovered from past surgeries.

My CML is in the chronic phase, confirmed by recent tests.

I can take care of myself and am up and about more than 50% of my waking hours.

My heart is healthy and I've had an ECG test in the last 42 days without major issues.

I was diagnosed with CML within the last 6 months and tested positive for the Philadelphia chromosome.

I have CML and have only been treated with hydroxyurea or anagrelide.

I haven't had chemotherapy for stem cell mobilization.

I do not have a history of serious bleeding disorders not related to my cancer.

I have no cancer history except for certain skin cancers, early-stage cancers in remission, or any cancer I've been free from for 5 years.

Dasatinib

Imatinib Mesylate

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer.

PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Chemotherapy for Breast Cancer

This study is evaluating whether a combination of drugs is more effective than a single drug in treating breast cancer.

I have had surgery to remove breast cancer and affected lymph nodes.

I haven't had cancer in the past 5 years, except for certain skin cancers or early-stage cervical or breast cancer.

My cancer is at an early or mid-stage and can be operated on.

I know my cancer's estrogen and progesterone receptor status.

My tumor is smaller than 1 cm and doesn't meet certain criteria.

I have breast cancer in both breasts, diagnosed within a month of each other, and the more advanced tumor meets the study criteria.

My breast cancer is confirmed and not spread beyond stage III.

My tumor is larger than 2 cm or larger than 1 cm with specific features.

My cancer has not spread to my lymph nodes and my tumor is at least 1 cm with high-risk features or larger than 2 cm.

My cancer has not spread to nearby tissues.

My breast cancer has not spread to underarm or breast nodes.

My breast cancer has spread to my lymph nodes.

Paclitaxel

This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard volume boost radiation therapy works compared to smaller volume boost radiation therapy when given together with chemotherapy in treating young patients who have undergone surgery for newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy with chemotherapy after surgery may kill any remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more effective than reduced-dose radiation therapy when given together with chemotherapy after surgery in treating young patients with medulloblastoma.

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Radiation + Chemotherapy for Medulloblastoma

This study is evaluating whether standard-dose radiation therapy works better than reduced-dose radiation therapy in treating young patients with medulloblastoma.

I have not had any radiotherapy treatments before.

My cancer, medulloblastoma, is confirmed and located in the back of my brain.

My condition is considered standard-risk.

My remaining cancer is smaller than 1.5 cm^2 and not widespread, confirmed by a recent MRI.

My cancer has not spread to my brain, spine, or cerebrospinal fluid.

I can perform most of my daily activities without help.

My bilirubin levels are within normal range for my age.

My liver enzymes are within normal limits for my age.

Cisplatin

Craniospinal Irradiation

Involved-Field Radiation Therapy

Lomustine

The purpose of this Phase III study is to evaluate the efficacy and safety of 3APS compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.

Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease

3APS for Alzheimer's Disease

This study is evaluating whether a drug called 3APS is safe and effective for people with Alzheimer's disease.

I have been diagnosed with Alzheimer's disease.

I am over 50, and if female, cannot have children.

I live at home or in assisted living with a caregiver who can help me.

I do not have any uncontrolled or significant medical conditions.

I have been on a stable dose of Alzheimer's medication for at least 4 months.

I can speak and write in English, French, or Spanish.

3APS

The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA [pVGI.1(VEGF2)] gene therapy administered using an experimental cardiac direct injection catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.

To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter

Gene Therapy for Angina

This study is evaluating whether a gene therapy can improve angina in patients.

I am eligible for standard procedures to restore blood flow.

I cannot come back for follow-up appointments.

I have severe chest pain that doesn't improve with medication.

I cannot or will not undergo heart-related tests involving catheters or nuclear methods.

My treatment areas can be safely targeted for therapy.

I have had a stroke or a mini-stroke in the last 60 days.

I have had recent issues with diabetic eye disease or wet age-related vision loss.

I am not willing to use condoms for a year after treatment.

I am not on medications that pose a high health risk.

I experience chest pain that limits my ability to exercise, but it's not heart-related.

I have uncontrolled heart rhythm problems.

I had a major heart attack within the last 60 days.

I have not had a recent heart attack or unstable chest pain.

I have a severe condition that limits my ability to exercise.

I have severe narrowing of my aortic valve or a mechanical heart valve.

I have had cancer or currently have cancer.

I felt chest pain during my exercise test.

pVGI.1(VEGF2)

Approved for 50 Other Conditions

This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). Surgery may be an effective treatment for LPHD. Drugs used in chemotherapy, such as doxorubicin, vincristine, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) with or without radiation therapy may kill more cancer cells.

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma

This study is evaluating whether surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease.

I have been newly diagnosed with LPHD and haven't received any treatment.

My cancer is in the early stage and hasn't grown large.

My cancer is at an early stage and has not formed a large tumor.

I agree not to breastfeed if I receive chemotherapy or radiation.

I am a woman who can have children and have a negative pregnancy test before starting treatment.

I haven't taken systemic corticosteroids in the last 30 days.

My creatinine level is not above 1.5 mg/dL.

I am pregnant or breastfeeding, have stage I cancer with one lymph node involved, and had a complete surgery.

University Of Rochester Clinical Trials 2022

Trials at this site

T900607-Sodium for Liver Cancer

Is this your site?

Is this your site?